Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DHEA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: DHEA. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2023-000224-10 Sponsor Protocol Number: PBKV.5zdnia03.08.2022 Start Date*: 2023-08-17
    Sponsor Name:The Pharmaceutical Company LEK-AM Sp. Zo.o.
    Full Title: A randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of a 12-week dose of 35 mg DHEA on quality of life in menopausal women.
    Medical condition: Menopause
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004250-15 Sponsor Protocol Number: Start Date*: 2018-06-08
    Sponsor Name:University Hospitals Birmingham
    Full Title: A prospective, phase II, single centre, cross-sectional, randomised trial investigating Dehydroepiandrosterone and it's Pharmacokinetics in Trauma
    Medical condition: DHEA depletion in trauma and hip fracture patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10056629 Dehydroepiandrosterone decreased PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-004160-16 Sponsor Protocol Number: PBKV.8zdnia01.06.2022 Start Date*: 2024-02-22
    Sponsor Name:The Pharmaceutical Company LEK-AM Sp. Zoo.
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality an...
    Medical condition: Menopause, sleep disorders in the postmenopausal period
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004397-27 Sponsor Protocol Number: 310741 Start Date*: 2007-10-19
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: Multi-center, double-blind, placebo-controlled study to investigate the efficacy and safety of daily oral 100 mg dehydroepiandrosterone (DHEA) over 6 treatment cycles as a concomitant therapy to or...
    Medical condition: Multi-center, double-blind, placebo-controlled study to investigate the efficacy and safety of daily oral 100 mg dehydroepiandrosterone (DHEA) over 6 treatment cycles as a concomitant therapy to or...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040477 Sexual dysfunction LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002425-21 Sponsor Protocol Number: 11054 Start Date*: 2012-02-10
    Sponsor Name:University of Nottingham
    Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging
    Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000115-10 Sponsor Protocol Number: SPON CU 086 Start Date*: 2005-10-14
    Sponsor Name:Cardiff University
    Full Title: A randomised, double blind, placebo-controlled, cross-over study of the effects of dehydroepiandrosterone replacement on vascular function in patients with primary and secondary adrenal insufficiency.
    Medical condition: Primary and secondary adrenal failure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018209-32 Sponsor Protocol Number: DHEA091209 Start Date*: 2010-02-17
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: EFFECTS OF DHEA TREATMENT ON ANTHROPOMETRIC AND METABOLIC PARAMETERS, AND ON QUALITY OF LIFE (QOL) IN PATIENTS WITH ADDISON S DISEASE UNDER GLUCORTICOID-MINERALCORTICOID SUBSTITUTIVE TREATMENT
    Medical condition: Addison s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056485 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003788-28 Sponsor Protocol Number: PR3079 Start Date*: 2007-11-05
    Sponsor Name:Pantarhei Bioscience B.V.
    Full Title: A double-blind, placebo controlled, randomized, comparative, mono-centre trial to assess the effects on the androgen metabolism and its effects on biochemical parameters, mood, fat, muscle and bone...
    Medical condition: Biochemical disturbances (androgens, lipids, bone markers, endocrine) and mood disturbances caused by the use of Oral Contraception (OC).
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000013-10 Sponsor Protocol Number: PR3042 Start Date*: 2007-03-14
    Sponsor Name:Pantarhei Bioscience B.V.
    Full Title: A double-blind, placebo controlled, randomised, comparative 2-way crossover study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual arousability and the...
    Medical condition: Sexual dysfunction caused by the use of oral contraceptives
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057671 Female sexual dysfunction LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003510-13 Sponsor Protocol Number: IRST174.08 Start Date*: 2013-05-07
    Sponsor Name:IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/A...
    Medical condition: pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004513-90 Sponsor Protocol Number: UMCN-AKF-14.07 Start Date*: 2015-03-17
    Sponsor Name:Radboud UMC
    Full Title: Optimizing abiraterone (Zytiga®) therapy by exploring the relation between an early biomarker - drug exposure - as a predictor for drug response in patients with mCRPC (OPTIMUM - STUDY)
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001310-34 Sponsor Protocol Number: OXY-COUP-PROT1.4 Start Date*: 2011-08-11
    Sponsor Name:Med. Univ. Wien, Univ. Klinik für Innere Med. III
    Full Title: Female Sexual Dysfunction in the Peri and Postmenopause: Effect of intranasal Oxytocin administration on sexual function and activity
    Medical condition: Sexual behaviour with reduced intercourse frequency due to female sexual function disorders
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007620-17 Sponsor Protocol Number: PR3083 Start Date*: 2008-02-19
    Sponsor Name:Pantarhei Bioscience BV
    Full Title: A double-blind, placebo-controlled, randomized, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual functioning in 6 women who experience a decr...
    Medical condition: Sexual dysfunction caused by the use of oral contraceptives
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057671 Female sexual dysfunction LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000716-30 Sponsor Protocol Number: RGL-003-001 Start Date*: 2020-09-10
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus ...
    Medical condition: Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BG (Completed) PL (Completed) CZ (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-017011-16 Sponsor Protocol Number: 0000000000000000000 Start Date*: 2011-06-16
    Sponsor Name:University Federico II
    Full Title: Treatment of the low IGF-1 syndrome associated with Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study
    Medical condition: Low serum IGF-I and GH deficiency in patients with congestive heart failure
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005033-29 Sponsor Protocol Number: CT/08.22 Start Date*: 2009-07-20
    Sponsor Name:Vassilis Georgoulias, Prof. of Internal Medicine-Oncology of Medical Dpt University of Crete
    Full Title: A PHASE II STUDY OF sunitinib IN PATIENTS WITH ADVANCED HORMONE RESISTANT AND CHEMOTHERAPY RESISTANT PROSTATE CANCER.
    Medical condition: Patients with advanced hormone resistant and chemotherapy resistant prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002087-24 Sponsor Protocol Number: CT/11.02 Start Date*: 2011-07-13
    Sponsor Name:Hellenic Oncology Research Group (HORG)
    Full Title: A phase II study of Temsirolimus in patients with advanced hormone - and chemotherapy - resistant prostate cancer.
    Medical condition: Advanced hormone - and chemotherapy - resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002063-26 Sponsor Protocol Number: METYX01 Start Date*: 2013-09-08
    Sponsor Name:S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano
    Full Title: A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma.
    Medical condition: Cushing's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004569-24 Sponsor Protocol Number: PR3082 Start Date*: 2008-09-29
    Sponsor Name:Pantarhei Bioscience BV
    Full Title: A double-blind, placebo-controlled, randomised, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on mood in women who experience mood disturbances duri...
    Medical condition: Biochemical disturbances (androgens, lipids, bone markers, endocrine) and mood distrubances caused by the use of Oral Contraception (OC).
    Disease:
    Population Age: Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001217-25 Sponsor Protocol Number: 2016-001217-25 Start Date*: 2016-09-07
    Sponsor Name:Uppsala University
    Full Title: Emotion, Serotonin and Premenstrual Dysphoric Disorder (EmSeP)
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:39:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA